Results 161 to 170 of about 3,304 (220)
Ciliary Motility Decreased by a CO2/HCO3--Free Solution in Ciliated Human Nasal Epithelial Cells Having a pH Elevated by Carbonic Anhydrase IV. [PDF]
Int J Mol SciOkamoto S +13 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Ophthalmology, 2014
To compare the intraocular pressure (IOP)-lowering efficacy and safety of brinzolamide 1% and brimonidine 0.2% fixed combination (BBFC) with that of brinzolamide 1% or brimonidine 0.2% monotherapy, all dosed 2 times per day (BID).Six-month, phase 3, randomized, multicenter, double-masked clinical trial.A total of 560 patients with primary open-angle ...
Tin Aung, Guna Laganovska, Ivan Goldberg
exaly +3 more sources
To compare the intraocular pressure (IOP)-lowering efficacy and safety of brinzolamide 1% and brimonidine 0.2% fixed combination (BBFC) with that of brinzolamide 1% or brimonidine 0.2% monotherapy, all dosed 2 times per day (BID).Six-month, phase 3, randomized, multicenter, double-masked clinical trial.A total of 560 patients with primary open-angle ...
Tin Aung, Guna Laganovska, Ivan Goldberg
exaly +3 more sources
Ophthalmology, 2008
To compare the safety and intraocular pressure (IOP)-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination with brinzolamide 1% or timolol 0.5% alone in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).Randomized, double-masked, parallel group, multicenter study.Five hundred twenty-three patients were randomized to the
Steven Ye Hua
exaly +3 more sources
To compare the safety and intraocular pressure (IOP)-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination with brinzolamide 1% or timolol 0.5% alone in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).Randomized, double-masked, parallel group, multicenter study.Five hundred twenty-three patients were randomized to the
Steven Ye Hua
exaly +3 more sources
Expert Opinion on Pharmacotherapy, 2008
Primary open-angle glaucoma is a multifactorial optic neuropathy characterized by the progressive loss of retinal ganglion cells and their axons. However, the primary risk factor is elevated intraocular pressure (IOP), which can damage the optic nerve head (ONH) and until now was the only treatable risk factor.
openaire +3 more sources
Primary open-angle glaucoma is a multifactorial optic neuropathy characterized by the progressive loss of retinal ganglion cells and their axons. However, the primary risk factor is elevated intraocular pressure (IOP), which can damage the optic nerve head (ONH) and until now was the only treatable risk factor.
openaire +3 more sources
Drugs & Aging, 2009
Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the beta-adrenergic receptor antagonist timolol. Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective ...
Jamie D, Croxtall, Lesley J, Scott
openaire +2 more sources
Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the beta-adrenergic receptor antagonist timolol. Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective ...
Jamie D, Croxtall, Lesley J, Scott
openaire +2 more sources
Preclinical Overview of Brinzolamide
Survey of Ophthalmology, 2000The development of topically active carbonic anhydrase inhibitors (CAIs) is a significant recent achievement in glaucoma medical treatment. Brinzolamide, the newest topical CAI, exhibits selectivity, high affinity, and potent inhibitory activity for the carbonic anhydrase type II isozyme (CA-II), which is involved in aqueous humor secretion.
openaire +2 more sources